Author Correction: An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
| Autor: | Aniebrys Marrero-Nodarse, Oliver Rassek, Kerstin Moehle, Arin Ghasparian, Armando Zuniga, John A. Robinson, Melissa Vrohlings |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
business.industry Immunology Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC581-607 Viral infection Virology Epitope Virus Peptide vaccines Infectious Diseases Medicine Pharmacology (medical) Immunologic diseases. Allergy Respiratory system business Author Correction RC254-282 |
| Zdroj: | NPJ Vaccines npj Vaccines, Vol 6, Iss 1, Pp 1-1 (2021) |
| ISSN: | 2059-0105 |
| Popis: | Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans, particularly in infants and the elderly. However, attempts to develop a safe and effective vaccine have so far been unsuccessful. Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are now known, including that bound by Motavizumab and its clinically used progenitor Palivizumab. We developed a chemically defined approach to RSV vaccine design, that allows control of both immunogenicity and safety features of the vaccine. Structure-guided antigen design and a synthetic nanoparticle delivery platform led to a vaccine candidate that elicits high titers of palivizumab-like, epitope-specific neutralizing antibodies. The vaccine protects preclinical animal models from RSV infection and lung pathology typical of vaccine-derived disease enhancement. The results suggest that the development of a safe and effective synthetic epitope-specific RSV vaccine may be feasible by combining this conformationally stabilized peptide and synthetic nanoparticle delivery system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|